Mutant KRAS was detected in only one of the DNA types in approximately half of the 30 patients, suggesting that liquid biopsy using evDNA can complement the current widely used patient evaluation methods for colon cancer with a minimal amount of DNA fragments. This evidence concerns the gene KRAS and malignant colon neoplasm.